Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 0.77 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.77 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.77 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.77 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.77 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.77 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.62 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.62 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6878041 | 0.91 | HDAC6 (0.79) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL18347206 | 0.90 | HDAC6 (0.80) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL15725419 | 0.90 | HDAC6 (0.80) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL23289011 | 0.89 | HDAC6 (0.78) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL17955695 | 0.88 | HDAC6 (0.84) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL18294914 | 0.87 | HDAC6 (0.67) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL18347205 | 0.87 | HDAC6 (1.00) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| Citarinostat SCHEMBL29882816 | 0.87 | HDAC6 (1.00) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| Citarinostat SCHEMBL2225863 | 0.87 | HDAC6 (1.00) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL18542592 | 0.86 | HDAC6 (0.59) | HDAC6HDAC3HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872227-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof | ACETYLON PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872227-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof | ACETYLON PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230364083-A1 | HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA | ACETYLON PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230364083-A1 | HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA | ACETYLON PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-11813261-B2 | HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia | ACETYLON PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813261-B2 | HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia | ACETYLON PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230190744-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230190744-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-11666568-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a BCL-2 inhibitor and methods of use thereof | ACETYLON PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666569-B2 | Treatment of polycystic diseases with an HDAC6 inhibitor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS) U.S. GOVERNMENT (US) | 2023-06-06 | — | — | US | disclosed |
| WO-2015054355-A1 | HDAC INHIBITORS, ALONE OR IN COMBINATION WITH PI3K INHIBITORS, FOR TREATING NON-HODGKIN'S LYMPHOMA | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015054175-A1 | COMBINATIONS OF HISTONE DEACTYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| US-20150105358-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150105384-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150105384-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | US | disclosed |
| WO-2015054197-A1 | HDAC INHIBITORS, ALONE OR IN COMBINATION WITH BTK INHIBITORS, FOR TREATING NON-HODGKIN'S LYMPHOMA | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015054099-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND EITHER HER2 INHIBITORS OR PI3K INHIBITORS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| US-20150105409-A1 | HDAC INHIBITORS, ALONE OR IN COMBINATION WITH BTK INHIBITORS, FOR TREATING NONHODGKIN'S LYMPHOMA | Acetylon Pharmaceticals, Inc. (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150099744-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND EITHER HER2 INHIBITORS OR PI3K INHIBITORS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | US | disclosed |
| US-20150099744-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND EITHER HER2 INHIBITORS OR PI3K INHIBITORS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105409-A1 | HDAC INHIBITORS, ALONE OR IN COMBINATION WITH BTK INHIBITORS, FOR TREATING NONHODGKIN'S LYMPHOMA | BTK, HDAC2, HDAC5 | HDAC6 7/4885HDAC3 10/4885HDAC1 8/4885 |
| US-20230364083-A1 | HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA | HDAC5, HDAC6, HDAC9 | HDAC6 2/4885HDAC3 8/4885HDAC1 7/4885 |
| US-11813261-B2 | HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia | BTK, HDAC2, HDAC4 | HDAC6 8/4885HDAC3 11/4885HDAC1 6/4885 |
| US-20230190744-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR AND METHODS OF USE THEREOF | HDAC1, HDAC3, HDAC8 | HDAC6 11/4885HDAC3 2/4885HDAC1 1/4885 |
| US-11666568-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a BCL-2 inhibitor and methods of use thereof | BCL2, HDAC1, HDAC3 | HDAC6 9/4885HDAC3 3/4885HDAC1 2/4885 |
| US-20150105384-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC2 | HDAC6 4/4885HDAC3 11/4885HDAC1 1/4885 |
| US-20150099744-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND EITHER HER2 INHIBITORS OR PI3K INHIBITORS | HDAC6, HDAC2, HDAC5 | HDAC6 1/4885HDAC3 7/4885HDAC1 6/4885 |
| US-11666569-B2 | Treatment of polycystic diseases with an HDAC6 inhibitor | HDAC6, PKD1, PKD2 | HDAC6 1/4885HDAC3 17/4885HDAC1 4/4885 |
| US-20150105358-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS | HDAC5, HDAC4, HDAC2 | HDAC6 10/4885HDAC3 6/4885HDAC1 5/4885 |
| US-11872227-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof | HDAC1, HDAC3, HDAC8 | HDAC6 4/4885HDAC3 2/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.